Suppression of topoisomerase IIα expression and function in human cells decreases chromosomal radiosensitivity

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 663, Issue 1-2, 2009, Pages 40-45

  Terry, Samantha Y A ^a   Riches, Andrew C ^a   Bryant, Peter E ^a  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

Chromatid breaks; G2 assay; Radiosensitivity; Topoisomerase II

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING) A; MESSENGER RNA; SMALL INTERFERING RNA; 2,3 BIS(3,5 DIOXO 1 PIPERAZINYL)BUTANE; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; PIPERAZINE DERIVATIVE; TUMOR ANTIGEN;

ARTICLE; CATALYSIS; CELL CYCLE G2 PHASE; CELL LYSATE; CHROMATID; CHROMATIN; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; MITOSIS; PRIORITY JOURNAL; RADIOSENSITIVITY; RNA TRANSCRIPTION; WESTERN BLOTTING; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; GAMMA RADIATION; GENETIC TRANSCRIPTION; HUMAN CHROMOSOME; IMMUNOHISTOCHEMISTRY; METABOLISM; MITOSIS INDEX; RADIATION DOSE; RADIATION EXPOSURE;

ANTIGENS, NEOPLASM; BLOTTING, WESTERN; CELL LINE; CHROMATIDS; CHROMOSOMES, HUMAN; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; GAMMA RAYS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MITOTIC INDEX; PIPERAZINES; RADIATION TOLERANCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC;

EID: 63549101281     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2009.01.003     Document Type: Article

References (52)

1. Scott D., Spreadborough A., Levine E., and Roberts S.A. Genetic predisposition to breast cancer. Lancet 344 (1994) 1444
2. Riches A.C., Bryant P.E., Steel C.M., Gleig A., Robertson A.J., Preece P.E., and Thompson A.M. Chromosomal radiosensitivity in G2-phase lymphocytes identifies breast cancer patients with distinctive tumour characteristics. Br J. Cancer 85 (2001) 1157-11561
3. Scott D., Barber J.B.P., Spreadborough A.R., Burrill W., and Roberts S.A. Increased radiosensitivity in breast cancer patients: a comparison of two assays. Int. J. Radiat. Biol. 75 (1999) 1-10
4. Roberts S.A., Spreadborough A.R., Bulman B., Barber J.B.P., Evans D.R.G., and Scott D. Heritability of cellular radiosensitivity: a marker of low penetrance predisposition genes in breast cancer?. Am. J. Hum. Genet. 65 (1999) 784-794
5. Baria K., Warren C., Roberts S.A., West C.M., and Scott D. Chromosomal radiosensitivity as a marker of predisposition to common cancers. Br. J. Cancer 84 (2001) 892-896
6. Terzoudi G.I., Jung T., Hain J., Vrouvas J., Margaritis K., Donta-Bakoyiannis C., Makropoulos V., Angelakis P.H., and Pantelias G.E. Increased chromosomal radiosensitivity in cancer patients: the role of cdk1/cyclin-B activity level in the mechanisms involved. Int. J. Radiat. Biol. 76 (2000) 607-615
7. Papworth R., Slevin N., Roberts S.A., and Scott D. Sensitivity to radiation-induced chromosome damage may be a marker of genetic predisposition in young head and neck cancer patients. Br. J. Cancer 84 (2001) 776-782
8. Buchholz T.A., and Wu X. Radiation-induced chromatid breaks as a predictor of breast cancer risk. Int. J. Radiat. Oncol. Biol. Phys. 49 (2001) 533-537
9. Baeyens A., Thierens H., Claes K., Poppe B., Messiaen L., de Ridder L., and Vral A. Chromosomal radiosensitivity in breast cancer patients with a known or putative genetic predisposition. Br. J. Cancer 87 (2002) 1379-1385
10. Baeyens A., Broecke R.V.D., Makar A., Thierens H., de Ridder L., and Vral A. Chromosomal radiosensitivity in breast cancer patients: influence of age of onset of the disease. Oncol. Rep. 13 (2005) 347-353
11. Howe O.L., Daly P.A., Seymour C., Ormiston W., Nolan C., and Mothersill C. Elevated G2 chromosomal radiosensitivity in Irish breast cancer patients: a comparison with other studies. Int. J. Radiat. Biol. 81 (2005) 373-378
12. Lisowska H., Lankoff A., Wieczorek A., Florek A., Kuszewski T., Góźdź S., and Wojcik A. Enhanced chromosomal radiosensitivity in peripheral blood lymphocytes of larynx cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 66 (2006) 1245-1252
13. De Ruyck K., de Gelder V., Van Eijkeren M., Boterberg T., De Neve W., Vral A., and Thierens H. Chromosomal radiosensitivity in head and neck cancer patients: evidence for genetic predisposition?. Br. J. Cancer 98 (2008) 1723-1738
14. Parshad R., Price F.M., Bohr V.A., Cowan R., Zujewski J.K.A., and Sanford K.K. Deficient DNA repair capacity, a predisposing factor in breast cancer. Br. J. Cancer 74 (1996) 1-5
15. Patel R.K., Trivedi A.H., Arora D.C., Bhatavdekar J.M., and Patel D.D. DNA repair proficiency in breast cancer patients and their first-degree relatives. Int. J. Cancer 73 (1997) 20-24
16. Bender A.M., Griggs H.G., and Bedford J.S. Mechanisms of chromosomal aberration production. III. Chemicals and ionizing radiation. Mut. Res. 23 (1974) 197-212
17. Bryant P.E., Gray L.J., and Peresse N. Progress towards understanding the nature of chromatid breakage. Cytogenet. Genome Res. 104 (2004) 65-71
18. Macleod R.A.F., and Bryant P.E. Similar kinetics of chromatid aberrations in X-irradiated xrs 5 and wild-type Chinese hamster cells. Mutagenesis 5 (1990) 407-410
19. Bryant P.E. The signal model: a possible explanation for the conversion of DNA double-strand breaks into chromatid breaks. Int. J. Radiat. Biol. 73 (1998) 243-251
20. Bryant P.E. Origin of chromosome aberrations: mechanisms. In: Obe G., and Vijayalaxmi (Eds). Chromosomal Alterations: Methods, Results and Importance in Human Health (2007), Springer-Verlag, Berlin, Heidelberg 177-199
21. Harvey A.N., and Savage J.R.K. Investigating the nature of chromatid breaks produced by restriction endonucleases. Int. J. Radiat. Biol. 71 (1997) 21-28
22. Mozdarani H., Liu N., Jones N.J., and Bryant P.E. The XRCC2 human repair gene influences recombinational rearrangments leading to chromatid breaks. Int. J. Radiat. Biol. 77 (2001) 859-865
23. Austin C.A., and Marsh K.L. Eukaryotic DNA topoisomerase II beta. Bioessays 20 (1998) 215-226
24. Li T., Chen A.Y., Mao Y., Wang H., and Liu L.F. Activation of topoisomerase II-mediated excision of chromosomal DNA loops during oxidatie stress. Genes Dev. 13 (1999) 1553-1560
25. Kingma P.S., Corbett A.H., Burcham P.C., Marnett L.J., and Osheroff N. Abasic sites stimulate double-stranded DNA cleavage mediated by topoisomerase II. J. Biol. Chem. 270 (1995) 21441-21444
26. Woessner R.D., Mattern M.R., Mirabelli C.K., Johnson R.K., and Drake F.H. Proliferation and cell cycle dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ. 2 (1991) 209-214
27. Liu L.F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58 (1989) 351-375
28. Chen A.Y., and Liu L.F. DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol. 34 (1994) 191-218
29. Chen G.L., Yang L., Rowe T.C., Halligan B.D., Tewey K.M., and Liu L.F. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J. Biol. Chem. 259 (1984) 13560-13566
30. Sabourin M., and Osheroff N. Sensitivity of human type II topoisomerases to DNA damage: stimulation of enzyme-mediated DNA cleavage by abasic, oxidized and alkylated lesions. Nucleic Acids Res. 28 (2000) 1947-1954
31. Osheroff N. Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide. Biochemistry 28 (1989) 6157-6160
32. McClendon A.K., and Osheroff N. DNA topoisomerase II, genotoxicity, and cancer. Mutat. Res. 623 (2007) 83-97
33. Felix C.A., Kolaris C.P., and Osheroff N. Topoisomerase II and the etiology of chromosome translocations. DNA Rep. 5 (2006) 1093-1108
34. Tanabe K., Ikegami Y., Ishida R., and Andoh T. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res. 51 (1991) 4903-4908
35. Mandraju R.K., Kannaapiran P., and Kondapi A.K. Distinct roles of topoisomerase II isoforms: DNA damage accelerating alpha, double-strand break repair promoting beta. Arch. Biochem. Biophys. 470 (2008) 27-34
36. Yang X., Li W., Prescott E.D., Burden S.J., and Wang J.C. DNA topoisomerase IIbeta and neural development. Science 287 (2000) 131-134
37. Terry S.Y., Riches A.C., and Bryant P.E. A role for topoisomerase II alpha in the formation of radiation-induced chromatid breaks. Br. J. Cancer 99 (2008) 670-674
38. Harker W.G., Slade D.L., Drake F.H., and Parr R.L. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform. Biochemistry 30 (1991) 9953-9961
39. Lang A.J., Mirski S.E., Cummings H.J., Yu Q., Gerlach J.H., and Cole S.P. Structural organization of the human TOP2A and TOP2B genes. Gene 221 (1998) 255-266
40. Xu J., Stolk J.A., Zhang X., Silva S.J., Houghton R.L., Matsumura M., Vedvick T.S., Leslie K.B., Badaro R., and Reed S.G. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res. 60 (2000) 1677-1682
41. Bryant P.E., Gray L., Riches A.C., Steel C.M., Finnon P., Howem O., Kesterton I., Vral A., Curwen G.B., Smart V., Tawn E.J., and Whitehouse C.A. The G2 chromosomal radiosensitivity assay. Int. J. Radiat. Biol. 78 (2002) 863-866
42. Davies S.M., Robson C.N., Davies S.L., and Hickson I.D. Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J. Biol. Chem. 263 (1998) 17724-17729
43. Ivanova E.C., Donev R.M., and Djondjurov L.P. Localisation of DNA topoisomerase IIalpha in mouse erythroleukemia cells. Mol. Cells 9 (1999) 309-313
44. Uemura T., Ohkura H., Adachi Y., Morino K., Shiozaki K., and Yanagida M. DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe. Cell 50 (1987) 917-925
45. Roca J., Ishida R., Berger J.M., Andoh T., and Wang J.C. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 1781-1785
46. Park I., and Avraham H.K. Cell cycle-dependent DNA damage signaling induced by ICRF-193 involves ATM, ATR, CHK2, and BRCA1. Exp. Cell Res. 312 (2006) 1996-2008
47. Perrin D., van Hille B., and Hill B.T. Differential sensitivities of recombinant human topoisomerase IIalpha and beta to various classes of topoisomerase II-interacting agents. Biochem. Pharmacol. 56 (1998) 503-507
48. Anderson H., and Roberge M. Topoisomerase II inhibitors affect entry into mitosis and chromosome condensation in BHK cells. Cell Growth Differ. 7 (1996) 83-90
49. Lei M., and Erikson R.L. Plk1 depletion in nontransformed diploid cells activates the DNA-damage checkpoint. Oncogene 27 (2008) 3935-3943
50. Pretazzoli V., Salone B., Bosi A., and Olivieri G. Variability of G2 checkpoint sensitivity to low doses of X-rays (2 cGy): correlation with G2 chromatid aberrations but not with an adaptive response. Mutagenesis 15 (2000) 531-535
51. Poljak L., and Kas E. Resolving the role of topoisomerase II in chromatin structure and function. Trends Cell Biol. 5 (1995) 348-354
52. Sutherland B.M., Bennett P.V., Sidorkina O., and Laval J. Clustered DNA damages induced in isolated DNA and human cells by low doses of ionizing radiation. PNAS 97 2000 (2000) 103-108